{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:16:28Z","timestamp":1792167388308,"version":"4.4.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ygyno.2025.03.034","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T22:39:08Z","timestamp":1743547148000},"page":"36-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer"],"prefix":"10.1016","volume":"196","author":[{"given":"Quang D.","family":"Ta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormozan (Zan)","family":"Sorooshian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merta","family":"Cushing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Kavecansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2025.03.034_bb0005","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.03.034_bb0010","series-title":"Cancer of the Endometrium - Cancer Stat Facts","year":"2025"},{"key":"10.1016\/j.ygyno.2025.03.034_bb0015","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2025.03.034_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.03.034_bb0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2021.04.034","article-title":"Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer","volume":"162","author":"How","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.03.034_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2023.09.010","article-title":"Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer","volume":"178","author":"Zammarrelli","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.03.034_bb0035","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/cancers12041010","article-title":"Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events","volume":"12","author":"Iwamoto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ygyno.2025.03.034_bb0040","series-title":"Lenvima (Lenvatinib) [Package Insert]. Nutley, NJ","year":"2021"},{"issue":"2","key":"10.1016\/j.ygyno.2025.03.034_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2022.02.020","article-title":"Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: a multicenter study in Korea","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2025.03.034_bb0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon-2023-0058","article-title":"Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA","volume":"20","author":"Wada","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2025.03.034_bb0055","article-title":"Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study","volume":"24","author":"Shang","year":"2024","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:28:29Z","timestamp":1777955309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":11,"alternative-id":["S0090825825001118"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.034","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}